Navigation Links
Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease
Date:12/12/2007

Data Suggest Continued Improvement in Motor Function at 24 Months

SAN DIEGO, Dec. 12 /PRNewswire/ -- Ceregene, Inc. today presented long-term follow-up data from a Phase 1 clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. CERE-120 uses gene therapy to deliver the neural growth factor neurturin to the major area of neurodegeneration that occurs in the brains of Parkinson's disease patients. Long-term follow up assessments at 18 and 24 months post treatment, suggest a sustained reduction in Parkinson's symptoms. It was previously reported that an average of 36 percent (p<0.001) reduction in Parkinson's symptoms was seen 12 months after CERE-120 administration. Of the 12 subjects treated, nine had shown a clinically meaningful reduction in symptoms at 12 months, and the mean improvement of these 'responders' at 12 months was 46 percent. Today it was reported that the eight evaluable responders exhibited a persistent mean improvement in symptoms of 52 percent at their longest time of follow-up (24 months for low-dose cohort and 18 months for high-dose cohort). More specifically, there was a statistically significant improvement in the primary endpoint compared to baseline (p<0.001) defined as the reduction in Parkinson's symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 continues to appear safe and well-tolerated, with no treatment-related or surgically-related serious adverse events reported for any of these patients. These data were presented today at the World Congress of Parkinson's Disease by Raymond T. Bartus, Ph.D., Ceregene's executive vice president of clinical and preclinical R&D and chief operating officer.

The Phase 1 trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites -- University of California, San Francisco
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... PALO ALTO, Calif., Feb. 9, 2011 Telik, Inc. (Nasdaq: ... Wick, M.D., Ph.D. will provide a corporate overview at the ... City on Tuesday, February 15 at 3:00 p.m. Eastern time ... A live and archived webcast of the presentation will be ...
... MATEO, Calif., Feb. 8, 2011 NeurogesX, Inc. (Nasdaq: ... developing and commercializing novel pain management therapies, announced today ... scheduled to present at two upcoming conferences in New ... Investor Conference, to be held February 14-15, 2011 at ...
Cached Medicine Technology:NeurogesX to Present at Two February Investor Conferences 2NeurogesX to Present at Two February Investor Conferences 3
(Date:5/24/2013)... 2013 This week is National EMS ... efforts to provide the best emergency care and to ... week is also to educate the public that all ... Citizens are the first link, and a very important ... CPR after a cardiac arrest can triple a victim’s ...
(Date:5/24/2013)... Pomona, Calif. (PRWEB) May 24, 2013 ... has retained its status of “Full Accreditation” for the ... (AVMA) Council on Education (COE). , “This is a ... of our hard work and student outcomes,” said College ... want to express my appreciation to the faculty, staff, ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Gift ... Cards, major competitors in sustainable card material, are ... using forest materials as a sustainable gift card ... to identify industry challenges and increase education and ... programs to support the reduction of carbon footprint ...
(Date:5/24/2013)... failed to replicate what appeared to be breakthrough results ... were published last year in the journal Science ... suggested that the drug bexarotene (marketed as Targretin) could ... a pathological hallmark of Alzheimer,s disease in ... the 2012 report, drug treatment quickly removed most of ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3
... SAN FRANCISCO, March 24 Epiphany Biosciences announced ... IND with the Food and Drug Administration (FDA) ... antiviral medication valomaciclovir (EPB-348) as an adjunctive therapy ... shown to possess potent antiviral activity in vitro ...
... Reverse Split Ratio of Outstanding Cellegy Common Stock Expected ... Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY) today announced ... Corporation approved the previously announced merger of the two ... The transaction, which is subject to customary closing ...
... and average selling prices to be affected into ... 24 According to Millennium Research Group,s (MRG,s) ... includes arthroplasty implants (shoulder, elbow, digit, ankle, and ... the double-digit market growth seen in recent years ...
... Calif., March 24 According to a new Harris ... being able to afford medical care and prescription medications.(1) ... children and working-age Americans went without needed prescription medications in ... in 2003. Experts predict these statistics are likely to ...
... Wuesthoff saves 16 percent system-wide on orthopedic spend , ... ... Wuesthoff Health System has renewed its supply chain relationship with Broadlane. ... of consumable supplies, equipment, pharmaceuticals and purchased services to help manage ...
... Regal International, Inc., doing business as Beauty ... by EMK Products, LLC to be the exclusive ... line. Under the agreement, Beauty Beverly Hills will ... and management of internet affiliates, marketing and sales.Beauty ...
Cached Medicine News:Health News:Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS) 2Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 2Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 3Health News:Job Loss Means Fewer Americans Have Health Care Coverage: How Will the Economic Downturn Affect the Small-Joint Implant Market? 2Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 2Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 3Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 4Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 2Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 3Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 4Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 2Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 3
... innovative capillary electrophoresis system is designed ... testing. The CAPILLARYS 2 utilizes liquid ... clinical diagnostic setting. Through continuous sample ... very narrow capillary tubes functioning concurrently, ...
... These unique Acid Fast Control ... smear with appropriate background material. ... a positive and negative smear. ... (Cat. No. 353), Ziehl-Neelsen or ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Medicine Products: